Literature DB >> 29025964

False-Positive Newborn Screening for Cystic Fibrosis and Health Care Use.

Robin Z Hayeems1,2, Fiona A Miller2, Marian Vermeulen3, Beth K Potter4, Pranesh Chakraborty5,6, Christine Davies6, June C Carroll7, Felix Ratjen8,9, Astrid Guttmann10,2,3,8,9.   

Abstract

OBJECTIVES: Evidence is mixed regarding the impact of false-positive (FP) newborn bloodspot screening (NBS) results on health care use. Using cystic fibrosis (CF) as an example, we determined the association of FP NBS results with health care use in infants and their mothers in Ontario, Canada.
METHODS: We conducted a population-based cohort study of all infants with FP CF results (N = 1564) and screen-negative matched controls (N = 6256) born between April 2008 and November 2012 using linked health administrative data. Outcomes included maternal and infant physician and emergency visits and inpatient hospitalizations from the infant's third to 15th month of age. Negative binomial regression tested associations of NBS status with outcomes, adjusting for infant and maternal characteristics.
RESULTS: A greater proportion of infants with FP results had >2 outpatient visits (16.2% vs 13.2%) and >2 hospital admissions (1.5% vs 0.7%) compared with controls; CF-related admissions and emergency department visits were not different from controls. Differences persisted after adjustment, with higher rates of outpatient visits (relative risk 1.39; 95% confidence interval 1.20-1.60) and hospital admissions (relative risk 1.67; 95% confidence interval 1.21-2.31) for FP infants. Stratified models indicated the effect of FP status was greater among those whose primary care provider was a pediatrician. No differences in health care use among mothers were detected.
CONCLUSIONS: Higher use of outpatient services among FP infants may relate to a lengthy confirmatory testing process or follow-up carrier testing. However, increased rates of hospitalization might signal heightened perceptions of vulnerability among healthy infants.
Copyright © 2017 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2017        PMID: 29025964     DOI: 10.1542/peds.2017-0604

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  8 in total

1.  Is surgical volume still the most accurate indicator of blood usage in the United States?

Authors:  Alexandra Savinkina; Mathew R P Sapiano; James Berger; Sridhar V Basavaraju
Journal:  Transfusion       Date:  2019-02-10       Impact factor: 3.157

2.  Parents' experience with positive newborn screening results for cystic fibrosis.

Authors:  Inken Brockow; Uta Nennstiel
Journal:  Eur J Pediatr       Date:  2019-03-09       Impact factor: 3.183

3.  Primary care providers' role in newborn screening result notification for cystic fibrosis.

Authors:  Robin Z Hayeems; Fiona A Miller; Carolyn J Barg; Yvonne Bombard; Pranesh Chakraborty; Beth K Potter; Sarah Patton; Jessica Peace Bytautas; Karen Tam; Louise Taylor; Elizabeth Kerr; Christine Davies; Jennifer Milburn; Felix Ratjen; Astrid Guttmann; June C Carroll
Journal:  Can Fam Physician       Date:  2021-06       Impact factor: 3.275

4.  Effect of newborn screening for critical CHD on healthcare utilisation.

Authors:  Rie Sakai-Bizmark; Hiraku Kumamaru; Eliza J Webber; Dennys Estevez; Laurie A Mena; Emily H Marr; Ruey-Kang R Chang
Journal:  Cardiol Young       Date:  2020-07-02       Impact factor: 1.093

5.  Newborn screening for cystic fibrosis: Role of primary care providers in caring for infants with positive screening results.

Authors:  June C Carroll; Robin Z Hayeems; Fiona A Miller; Carolyn J Barg; Yvonne Bombard; Pranesh Chakraborty; Beth K Potter; Jessica Peace Bytautas; Karen Tam; Louise Taylor; Elizabeth Kerr; Christine Davies; Jennifer Milburn; Felix Ratjen; Astrid Guttmann
Journal:  Can Fam Physician       Date:  2021-06       Impact factor: 3.275

Review 6.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

Review 7.  Constructing a Bioethical Framework to Evaluate and Optimise Newborn Bloodspot Screening for Cystic Fibrosis.

Authors:  Rachael E Armstrong; Lucy Frith; Fiona M Ulph; Kevin W Southern
Journal:  Int J Neonatal Screen       Date:  2020-05-26

8.  Performance of a Three-Tier (IRT-DNA-IRT) Cystic Fibrosis Screening Algorithm in British Columbia.

Authors:  Graham Sinclair; Vanessa McMahon; Amy Schellenberg; Tanya N Nelson; Mark Chilvers; Hilary Vallance
Journal:  Int J Neonatal Screen       Date:  2020-06-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.